Vaccine against autoimmune disease: Antigen-specific immunotherapy

Current Opinion in Immunology

Volumn 25, Issue 3, 2013, Pages 410-417

  Anderson, Robert P ^a   Jabri, Bana ^b  

^a ImmusanT Inc   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

ALLERGIC DISEASE; ANTIGEN SPECIFIC IMMUNOTHERAPY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELIAC DISEASE; DISEASE MODEL; DRUG EFFICACY; DRUG MONITORING; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH2 CELL;

ANIMALS; ANTIGENS; AUTOIMMUNE DISEASES; CELIAC DISEASE; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY; VACCINES;

EID: 84879245899     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2013.02.004     Document Type: Review

References (78)

1. Kurup V.P., Shen H.D., Banerjee B. Respiratory fungal allergy. Microbes Infect 2000, 2:1101-1110.
2. Prakken B.J., Samodal R., Le T.D., Giannoni F., Yung G.P., Scavulli J., Amox D., Roord S., de Kleer I., Bonnin D., et al. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci U S A 2004, 101:4228-4233.
3. Durham S.R., Walker S.M., Varga E.M., Jacobson M.R., O'Brien F., Noble W., Till S.J., Hamid Q.A., Nouri-Aria K.T. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999, 341:468-475.
4. Bousquet J., Lockey R., Malling H.J. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998, 102(Pt 1):558-562.
5. Joint Task Force on Practice Parameters, et al. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol 2007, 120(Suppl.):S25-S85.
6. Worm M., Lee H.H., Kleine-Tebbe J., Hafner R.P., Laidler P., Healey D., Buhot C., Verhoef A., Maillere B., Kay A.B., et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol 2011, 127:89-97. 97 e1-e14.
7. Patel D., Couroux P., Hickey P., Salapatek A.M., Laidler P., Larche M., Hafner R.P. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol 2013, 131:103-109. e7.
8. Arif S., Tree T.I., Astill T.P., Tremble J.M., Bishop A.J., Dayan C.M., Roep B.O., Peakman M. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004, 113:451-463.
9. Wherrett D.K., Bundy B., Becker D.J., DiMeglio L.A., Gitelman S.E., Goland R., Gottlieb P.A., Greenbaum C.J., Herold K.C., Marks J.B., et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011, 378:319-327.
10. Ludvigsson J., Krisky D., Casas R., Battelino T., Castano L., Greening J., Kordonouri O., Otonkoski T., Pozzilli P., Robert J.J., et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 2012, 366:433-442.
11. Pulendran B., Artis D. New paradigms in type 2 immunity. Science 2012, 337:431-435.
12. Jager A., Kuchroo V.K. Effector and regulatory T-cell subsets in autoimmunity and tissue inflammation. Scand J Immunol 2010, 72:173-184.
13. Kalinski P., Hilkens C.M., Wierenga E.A., Kapsenberg M.L. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 1999, 20:561-567.
14. Matzinger P., Kamala T. Tissue-based class control: the other side of tolerance. Nat Rev Immunol 2011, 11:221-230.
15. Yamane H., Paul W.E. Memory CD4+ T cells: fate determination, positive feedback and plasticity. Cell Mol Life Sci 2012, 69:1577-1583.
16. Jenkins M.K., Pardoll D.M., Mizuguchi J., Quill H., Schwartz R.H. T-cell unresponsiveness in vivo and in vitro: fine specificity of induction and molecular characterization of the unresponsive state. Immunol Rev 1987, 95:113-135.
17. Frauwirth K.A., Thompson C.B. Activation and inhibition of lymphocytes by costimulation. J Clin Invest 2002, 109:295-299.
18. Agardh C.D., Cilio C.M., Lethagen A., Lynch K., Leslie R.D., Palmer M., Harris R.A., Robertson J.A., Lernmark A. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005, 19:238-246.
19. Ludvigsson J., Faresjo M., Hjorth M., Axelsson S., Cheramy M., Pihl M., Vaarala O., Forsander G., Ivarsson S., Johansson C., et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008, 359:1909-1920.
20. Orban T., Farkas K., Jalahej H., Kis J., Treszl A., Falk B., Reijonen H., Wolfsdorf J., Ricker A., Matthews J.B., et al. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun 2010, 34:408-415.
21. Battaglia M., Roncarolo M.G. Immune intervention with T regulatory cells: past lessons and future perspectives for type 1 diabetes. Semin Immunol 2011, 23:182-194.
22. Belkaid Y., Oldenhove G. Tuning microenvironments: induction of regulatory T cells by dendritic cells. Immunity 2008, 29:362-371.
23. Josefowicz S.Z., Lu L.F., Rudensky A.Y. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012, 30:531-564.
24. Yamaguchi T., Wing J.B., Sakaguchi S. Two modes of immune suppression by Foxp3(+) regulatory T cells under inflammatory or non-inflammatory conditions. Semin Immunol 2011, 23:424-430.
25. Maynard C.L., Weaver C.T. Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation. Immunol Rev 2008, 226:219-233.
26. Roncarolo M.G., Gregori S., Battaglia M., Bacchetta R., Fleischhauer K., Levings M.K. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006, 212:28-50.
27. da Silva Martins M., Piccirillo C.A. Functional stability of Foxp3+ regulatory T cells. Trends Mol Med 2012, 18:454-462.
28. Jabri B., Sollid L.M. Tissue-mediated control of immunopathology in coeliac disease. Nat Rev Immunol 2009, 9:858-870.
29. Ruprecht C.R., Gattorno M., Ferlito F., Gregorio A., Martini A., Lanzavecchia A., Sallusto F. Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J Exp Med 2005, 201:1793-1803.
30. Benahmed M., Meresse B., Arnulf B., Barbe U., Mention J.J., Verkarre V., Allez M., Cellier C., Hermine O., Cerf-Bensussan N. Inhibition of TGF-beta signaling by IL-15: a new role for IL-15 in the loss of immune homeostasis in celiac disease. Gastroenterology 2007, 132:994-1008.
31. Hjorth M., Axelsson S., Ryden A., Faresjo M., Ludvigsson J., Casas R. GAD-alum treatment induces GAD65-specific CD4+ CD25highFOXP3+ cells in type 1 diabetic patients. Clin Immunol 2011, 138:117-126.
32. Pot C., Apetoh L., Kuchroo V.K. Type 1 regulatory T cells (Tr1) in autoimmunity. Semin Immunol 2011, 23:202-208.
33. Depaolo R.W., Tang F., Kim I., Han M., Levin N., Ciletti N., Lin A., Anderson D., Schneewind O., Jabri B. Toll-like receptor 6 drives differentiation of tolerogenic dendritic cells and contributes to LcrV-mediated plague pathogenesis. Cell Host Microbe 2008, 4:350-361.
34. Akdis M., Verhagen J., Taylor A., Karamloo F., Karagiannidis C., Crameri R., Thunberg S., Deniz G., Valenta R., Fiebig H., et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004, 199:1567-1575.
35. Oldfield W.L., Larche M., Kay A.B. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002, 360:47-53.
36. Campbell J.D., Buckland K.F., McMillan S.J., Kearley J., Oldfield W.L., Stern L.J., Gronlund H., van Hage M., Reynolds C.J., Boyton R.J., et al. Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med 2009, 206:1535-1547.
37. Wambre E., DeLong J.H., James E.A., LaFond R.E., Robinson D., Kwok W.W. Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy. J Allergy Clin Immunol 2012, 129:544-551. 551 e1-e7.
38. Thrower S.L., James L., Hall W., Green K.M., Arif S., Allen J.S., Van-Krinks C., Lozanoska-Ochser B., Marquesini L., Brown S., et al. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study. Clin Exp Immunol 2009, 155:156-165.
39. Ouyang W., Ranganath S.H., Weindel K., Bhattacharya D., Murphy T.L., Sha W.C., Murphy K.M. Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism. Immunity 1998, 9:745-755.
40. Raz I., Elias D., Avron A., Tamir M., Metzger M., Cohen I.R. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001, 358:1749-1753.
41. Cheramy M., Skoglund C., Johansson I., Ludvigsson J., Hampe C.S., Casas R. GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution: GAD65 enzyme activity and humoral response. Clin Immunol 2010, 137:31-40.
42. Axelsson S., Hjorth M., Akerman L., Ludvigsson J., Casas R. Early induction of GAD(65)-reactive Th2 response in type 1 diabetic children treated with alum-formulated GAD(65). Diabetes Metab Res Rev 2010, 26:559-568.
43. Qin S., Cobbold S.P., Pope H., Elliott J., Kioussis D., Davies J., Waldmann H. "Infectious" transplantation tolerance. Science 1993, 259:974-977.
44. Alpan O., Bachelder E., Isil E., Arnheiter H., Matzinger P. 'Educated' dendritic cells act as messengers from memory to naive T helper cells. Nat Immunol 2004, 5:615-622.
45. Hoyne G.F., Dallman M.J., Lamb J.R. Linked suppression in peripheral T cell tolerance to the house dust mite derived allergen Der p 1. Int Arch Allergy Immunol 1999, 118:122-124.
46. Gregori S., Goudy K.S., Roncarolo M.G. The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells. Front Immunol 2012, 3:30.
47. Dutton R.W., Bradley L.M., Swain S.L. T cell memory. Annu Rev Immunol 1998, 16:201-223.
48. Farber D.L. Biochemical signaling pathways for memory T cell recall. Semin Immunol 2009, 21:84-91.
49. Liblau R., Tisch R., Bercovici N., McDevitt H.O. Systemic antigen in the treatment of T-cell-mediated autoimmune diseases. Immunol Today 1997, 18:599-604.
50. Sadegh-Nasseri S., Dalai S.K., Korb Ferris L.C., Mirshahidi S. Suboptimal engagement of the T-cell receptor by a variety of peptide-MHC ligands triggers T-cell anergy. Immunology 2010, 129:1-7.
51. DePaolo R.W., Abadie V., Tang F., Fehlner-Peach H., Hall J.A., Wang W., Marietta E.V., Kasarda D.D., Waldmann T.A., Murray J.A., et al. Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens. Nature 2011, 471:220-224.
52. Noble J.A., Valdes A.M., Cook M., Klitz W., Thomson G., Erlich H.A. The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. Am J Hum Genet 1996, 59:1134-1148.
53. Sollid L.M., Markussen G., Ek J., Gjerde H., Vartdal F., Thorsby E. Evidence for a primary association of celiac disease to a particular HLA-DQ alpha/beta heterodimer. J Exp Med 1989, 169:345-350.
54. Karell K., Louka A.S., Moodie S.J., Ascher H., Clot F., Greco L., Ciclitira P.J., Sollid L.M., Partanen J. HLA types in celiac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease. Hum Immunol 2003, 64:469-477. European Genetics Cluster on Celiac Disease.
55. Sollid L.M., Jabri B. Celiac disease and transglutaminase 2: a model for posttranslational modification of antigens and HLA association in the pathogenesis of autoimmune disorders. Curr Opin Immunol 2011, 23:732-738.
56. Molberg O., McAdam S.N., Korner R., Quarsten H., Kristiansen C., Madsen L., Fugger L., Scott H., Noren O., Roepstorff P., et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med 1998, 4:713-717.
57. Hovhannisyan Z., Weiss A., Martin A., Wiesner M., Tollefsen S., Yoshida K., Ciszewski C., Curran S.A., Murray J.A., David C.S., et al. The role of HLA-DQ8 beta57 polymorphism in the anti-gluten T-cell response in coeliac disease. Nature 2008, 456:534-538.
58. Anderson R.P., Degano P., Godkin A.J., Jewell D.P., Hill A.V. In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nat Med 2000, 6:337-342.
59. Arentz-Hansen H., Korner R., Molberg O., Quarsten H., Vader W., Kooy Y.M., Lundin K.E., Koning F., Roepstorff P., Sollid L.M., et al. The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J Exp Med 2000, 191:603-612.
60. Tye-Din J.A., Stewart J.A., Dromey J.A., Beissbarth T., van Heel D.A., Tatham A., Henderson K., Mannering S.I., Gianfrani C., Jewell D.P., et al. Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease. Sci Transl Med 2010, 2:41ra51.
61. Sabatos-Peyton C.A., Verhagen J., Wraith D.C. Antigen-specific immunotherapy of autoimmune and allergic diseases. Curr Opin Immunol 2010, 22:609-615.
62. Larche M., Wraith D.C. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 2005, 11(Suppl.):S69-S76.
63. Lundin K.E., Scott H., Hansen T., Paulsen G., Halstensen T.S., Fausa O., Thorsby E., Sollid L.M. Gliadin-specific: HLA-DQ (alpha 1*0501,beta 1*0201) restricted T cells isolated from the small intestinal mucosa of celiac disease patients. J Exp Med 1993, 178:187-196.
64. Jensen K., Sollid L.M., Scott H., Paulsen G., Kett K., Thorsby E., Lundin K.E. Gliadin-specific T cell responses in peripheral blood of healthy individuals involve T cells restricted by the coeliac disease associated DQ2 heterodimer. Scand J Immunol 1995, 42:166-170.
65. Franco A., Appella E., Kagnoff M.F., Chowers Y., Sakaguchi K., Grey H.M., Sette A. Peripheral T cell response to A-gliadin in celiac disease: differential processing and presentation capacities of Epstein-Barr-transformed B cells and fibroblasts. Clin Immunol Immunopathol 1994, 71:75-81.
66. Yang J., James E.A., Sanda S., Greenbaum C., Kwok W.W. CD4+ T cells recognize diverse epitopes within GAD65: implications for repertoire development and diabetes monitoring. Immunology 2012, 138:269-279.
67. Tollefsen S., Arentz-Hansen H., Fleckenstein B., Molberg O., Raki M., Kwok W.W., Jung G., Lundin K.E., Sollid L.M. HLA-DQ2 and -DQ8 signatures of gluten T cell epitopes in celiac disease. J Clin Invest 2006, 116:2226-2236.
68. Kooy-Winkelaar Y., van Lummel M., Moustakas A.K., Schweizer J., Mearin M.L., Mulder C.J., Roep B.O., Drijfhout J.W., Papadopoulos G.K., van Bergen J., et al. Gluten-specific T cells cross-react between HLA-DQ8 and the HLA-DQ2alpha/DQ8beta transdimer. J Immunol 2011, 187:5123-5129.
69. Butterfield L.H., Palucka A.K., Britten C.M., Dhodapkar M.V., Hakansson L., Janetzki S., Kawakami Y., Kleen T.O., Lee P.P., Maccalli C., et al. Recommendations from the iSBTc-SITC/FDA/NCI workshop on immunotherapy biomarkers. Clin Cancer Res 2011, 17:3064-3076.
70. Mannering S.I., Harrison L.C., Williamson N.A., Morris J.S., Thearle D.J., Jensen K.P., Kay T.W., Rossjohn J., Falk B.A., Nepom G.T., et al. The insulin A-chain epitope recognized by human T cells is posttranslationally modified. J Exp Med 2005, 202:1191-1197.
71. Kent S.C., Chen Y., Bregoli L., Clemmings S.M., Kenyon N.S., Ricordi C., Hering B.J., Hafler D.A. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 2005, 435:224-228.
72. James E.A., Mallone R., Schloot N.C., Gagnerault M.C., Thorpe J., Fitzgerald-Miller L., Reichow J., Wagner R., Pham M.N., Jospe N., et al. Immunology of diabetes society T-cell workshop: HLA class II tetramer-directed epitope validation initiative. Diabetes Metab Res Rev 2011, 27:727-736.
73. Mallone R., Scotto M., Janicki C.N., James E.A., Fitzgerald-Miller L., Wagner R., Gottlieb P., Thorpe J., Jospe N., Durinovic-Bello I., et al. Immunology of diabetes society T-cell workshop: HLA class I tetramer-directed epitope validation initiative T-cell workshop report-HLA class I tetramer validation initiative. Diabetes Metab Res Rev 2011, 27:720-726.
74. Moodie Z., Price L., Gouttefangeas C., Mander A., Janetzki S., Lower M., Welters M.J., Ottensmeier C., van der Burg S.H., Britten C.M. Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother 2010, 59:1489-1501.
75. Olson W.C., Smolkin M.E., Farris E.M., Fink R.J., Czarkowski A.R., Fink J.H., Chianese-Bullock K.A., Slingluff C.L. Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function. J Transl Med 2011, 9:26.
76. Filbert H., Attig S., Bidmon N., Renard B.Y., Janetzki S., Sahin U., Welters M.J., Ottensmeier C., van der Burg S.H., Gouttefangeas C., et al. Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols. Cancer Immunol Immunother 2012, 10.1007/s00262-012-1359-5.
77. Britten C.M., Janetzki S., Butterfield L.H., Ferrari G., Gouttefangeas C., Huber C., Kalos M., Levitsky H.I., Maecker H.T., Melief C.J., et al. T cell assays and MIATA: the essential minimum for maximum impact. Immunity 2012, 37:1-2.
78. Bonvalet M., Moussu H., Wambre E., Ricarte C., Horiot S., Rimaniol A.C., Kwok W.W., Horak F., de Beaumont O., Baron-Bodo V., et al. Allergen-specific CD4+ T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapy. Clin Exp Allergy 2012, 42:1745-1755.